Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hillevax Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.hillevax.com/
Year Founded: 2021
Status: Public
Industry Sector: HealthTechnology
CEO: Robert M. Hershberg, MD, PhD
Number Of Employees: 90
Enterprise Value: $399,315,636
PE Ratio: -0.56
Exchange/Ticker 1: NASDAQ:HLVX
Exchange/Ticker 2: N/A
Latest Market Cap: $85,666,496
BioCentury | Oct 4, 2024
Finance
3Q24 Wrap: Lookin’ up at last
Winners, losers in biotech stock tiers in 3Q24
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Jul 10, 2024
Product Development
Clinical Report: uniQure’s Huntington readout, Ideaya’s MAT2A data drive shares up
Plus: A HilleVax vaccine disappoints, and another TIGIT miss for Genentech
BioCentury | Jan 19, 2024
Management Tracks
GSK vet McLoughlin joins HilleVax as COO
Plus: Acadia alum Stankovic passes away and updates for AZ, Immunitas, Iktos, Certis and PepGen
BioCentury | Feb 3, 2023
Finance
Strong demand in spotlight for Structure IPO
Upsized deal gives GPCR play fourth-largest NASDAQ debut in a year
BioCentury | Jan 11, 2023
Management Tracks
Kevin Tan becomes CFO at Solid
Plus: Shook promoted to CMO at Nkarta, and updates from HilleVax, Neurotech, Akero, LifeSci, Dunad and more
BioCentury | Sep 15, 2022
Finance
Third Harmonic IPO could signal a reopening window for NASDAQ listings
Clinical developer of c-Kit program for hives and asthma raises $185M in upsized offering, gains in first trading day
BioCentury | Sep 9, 2022
Finance
After quiet season for IPOs, Third Harmonic set to test investor appetite
The three-year-old biotech, advancing a c-Kit inhibitor to treat hives, could be the first to raise at least $150M in a NASDAQ IPO since April
BioCentury | Jul 6, 2022
Data Byte
Handful of biotechs squeeze through IPO window in 2Q22
Five biotech companies priced IPOs in 2Q22, led by HilleVax
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
Items per page:
1 - 10 of 15